Catalan
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
atrophic vaginitis/progesterona
L'enllaç es desa al porta-retalls
Pàgina 1 des de 35 resultats
Ex Vivo Evaluation of Intravaginal Progesterone and Testosterone to Treat the Luteal-phase Deficiency and Vaginal Atrophy.
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
The purpose of this study was to evaluate the transmucosal permeation of progesterone and testosterone using Pentravan as its vehicle for vaginal delivery. Progesterone deficiency is a hormone imbalance that could lead to luteal-phase deficiency, which is a common problem in assisted reproductive
Efficacy and safety of vaginal estriol and progesterone in postmenopausal women with atrophic vaginitis.
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
OBJECTIVE
The aim of this study was to assess the efficacy and safety of intravaginal estriol and progesterone on atrophic vaginitis in postmenopausal women.
METHODS
Under a physician-sponsored Investigational New Drug application, 19 healthy postmenopausal women with atrophic vaginitis received
Vaginal stromal sclerosis: a distinctive stromal change associated with vaginal atrophy.
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
The author describes 3 cases of an unusual vaginal lesion, designated as "vaginal stromal sclerosis," that is believed to represent a clinically and pathologically distinct disease. The 3 patients, aged 62, 52, and 50 years, all presented with dyspareunia and had clinical evidence of vaginal
Treatment of menopausal symptoms with three low-dose continuous sequential 17β-estradiol/progesterone parenteral monthly formulations using novel non-polymeric microsphere technology.
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
OBJECTIVE
To analyze the short-term efficacy and safety over menopausal symptoms of three low-dose continuous sequential 17β-estradiol (E)/progesterone (P) parental monthly formulations using novel non-polymeric microspheres.
METHODS
This was a multicenter, randomized, single blinded study in which
A comparison of raloxifene and calcium plus vitamin D on vaginal atrophy after discontinuation of long-standing postmenopausal hormone therapy in osteoporotic women. A randomized, masked-evaluator, one-year, prospective study.
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
OBJECTIVE
We assessed the effects of the discontinuation of long-standing transdermal estrogen replacement therapy (>4 years) and substitution of this treatment by calcium or raloxifene on the vaginal epithelium and climateric symptoms in a study population of osteoporotic women.
METHODS
A total of
Topical progesterone in treatment of vulvar dystrophy: preliminary report of five cases.
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
Topical progesterone was used in five cases of chronic vulvar dystrophy which were confirmed by biopsy. Good results were obtained in three of the cases through the sole use of topical progesterone. In one case, topical testosterone was substituted for the progesterone, and it was not as effective.
Menopausal hormone replacement therapy with continuous daily oral micronized estradiol and progesterone.
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
The safety and efficacy of a daily combination of micronized estradiol (E2) (0.7-1.05 mg) and progesterone (200-300 mg) were evaluated in ten menopausal women with moderate to severe vasomotor symptoms and/or vaginal atrophy over a 12-month study interval. For comparison, five similar women were
Biopsychosocial predictors of postmenopausal dyspareunia: the role of steroid hormones, vulvovaginal atrophy, cognitive-emotional factors, and dyadic adjustment.
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
BACKGROUND
Although dyspareunia experienced after menopause is widely attributed to declining estrogen levels and vulvovaginal atrophy, critical reviews of the literature have suggested that these factors are incomplete as explanatory mechanisms. Little is known about psychosocial factors that may
The role of hormone replacement therapy in women with a previous diagnosis of breast cancer and a review of possible alternatives.
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
Estrogen replacement therapy either with (HRT) or without (ERT) accompanying progesterone is routinely offered to well women at the time of menopause, in order to relieve vasomotor symptoms, (hot flashes), reduce urogenital atrophy and reduce the risks of cardiovascular disease, osteoporosis and
[Oestrogen for prevention of recurrent urinary tract infections in postmenopausal women--a survey of a Cochrane review].
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
Recurrent urinary tract infections (UTIs) are common in postmenopausal women. While the pathophysiology is often complex, it is evident that the urogenital atrophy due to the decrease of endogenous oestrogen production is a key factor. Two small randomized controlled studies have proven the efficacy
Estrogens and the lower urinary tract.
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
The urogenital tract is sensitive to the effect of oestrogen and progesterone throughout adult life. Epidemiological studies have implicated oestrogen deficiency in the aetiology of lower urinary tract symptoms occurring following the menopause. Although to date the role of oestrogen replacement
[Hormone therapy in menopause: when not to use].
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
Menopause is defined as the permanent cessation of menses, as a result of the loss of ovarian follicular function or of surgical removal of ovaries. The mean age for occurrence of natural menopause is around 50 years. Estrogen deficiency has been associated with vasomotor symptoms, urogenital
Psychosexual effects of menopause: role of androgens.
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
Ovarian hormones-estrogens, androgens, and progesterone-produce a myriad of effects in the nervous system. The effects of androgens in the brain are mediated through androgen-specific receptors and by the aromatization of testosterone to estradiol. Alterations in the circulating levels of androgens
Vaginal rings for menopausal symptom relief.
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
The vagina is an alternative delivery site of sex steroids for menopausal women. New ring technology provides continuous and consistent delivery of steroids for up to 3 months. Rings rest on the pelvic floor muscles in a nearly horizontal position and are usually imperceptible. Steroid is delivered
Progestogens in postmenopausal hormone therapy and the risk of breast cancer.
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
Hormone therapy is the treatment of choice for the alleviation of menopausal symptoms and the treatment of urogenital atrophy. In women with an intact uterus a progestogen must be added to estrogen therapy to prevent endometrial hyperplasia and cancer. There is a wide variety of marketed
La base de dades d’herbes medicinals més completa avalada per la ciència
- Funciona en 55 idiomes
- Cures a base d'herbes recolzades per la ciència
- Reconeixement d’herbes per imatge
- Mapa GPS interactiu: etiqueta les herbes a la ubicació (properament)
- Llegiu publicacions científiques relacionades amb la vostra cerca
- Cerqueu herbes medicinals pels seus efectes
- Organitzeu els vostres interessos i estigueu al dia de les novetats, els assajos clínics i les patents
Escriviu un símptoma o una malaltia i llegiu sobre herbes que us poden ajudar, escriviu una herba i vegeu malalties i símptomes contra els quals s’utilitza.
* Tota la informació es basa en investigacions científiques publicades
